Methods to assess COPD medications adherence in healthcare databases: a systematic review

Background: The Global Initiative for Chronic Obstructive Lung Disease 2023 report recommends medication adherence assessment in COPD as an action item. Healthcare databases provide opportunities for objective assessments; however, multiple methods exist. We aimed to systematically review the literature to describe existing methods to assess adherence in COPD in healthcare databases and to evaluate the reporting of influencing variables. Method: We searched MEDLINE, Web of Science and Embase for peer-reviewed articles evaluating adherence to COPD medication in electronic databases, written in English, published up to 11 October 2022 (PROSPERO identifier CRD42022363449). Two reviewers independently conducted screening for inclusion and performed data extraction. Methods to assess initiation (dispensing of medication after prescribing), implementation (extent of use over a specific time period) and/or persistence (time from initiation to discontinuation) were listed descriptively. Each included study was evaluated for reporting variables with an impact on adherence assessment: inpatient stays, drug substitution, dose switching and early refills. Results: 160 studies were included, of which four assessed initiation, 135 implementation and 45 persistence. Overall, one method was used to measure initiation, 43 methods for implementation and seven methods for persistence. Most of the included implementation studies reported medication possession ratio, proportion of days covered and/or an alteration of these methods. Only 11% of the included studies mentioned the potential impact of the evaluated variables. Conclusion: Variations in adherence assessment methods are common. Attention to transparency, reporting of variables with an impact on adherence assessment and rationale for choosing an adherence cut-off or treatment gap is recommended. Tweetable abstract Methods to assess adherence to COPD medication in healthcare databases are presented. More attention should be paid to the impact of inpatient stays, drug substitution, dose switching and early medication refills on adherence assessment. https://bit.ly/3q9b1VR

[1]  L. Lahousse,et al.  In-hospital antibiotic use for severe chronic obstructive pulmonary disease exacerbations: a retrospective observational study , 2023, BMC Pulmonary Medicine.

[2]  Chang-Hoon Lee,et al.  Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea , 2022, Respiratory Research.

[3]  N. Snowise,et al.  Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting , 2022, International journal of chronic obstructive pulmonary disease.

[4]  L. van Dijk,et al.  Better use of inhaled medication in asthma and COPD through training, preparation and counselling: the On TRACk study protocol for a cluster randomised controlled trial , 2022, BMJ Open.

[5]  A. Sicras-Mainar,et al.  Clinical characteristics, treatment persistence and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. , 2022, Chest.

[6]  D. Qato,et al.  Prediction of treatment nonadherence among older adults with chronic obstructive pulmonary disease using Medicare real-world data , 2022, Journal of managed care & specialty pharmacy.

[7]  Samuel S. Allemann,et al.  Methodological considerations on estimating medication adherence from self‐report, electronic monitoring and electronic healthcare databases using the TEOS framework , 2022, British journal of clinical pharmacology.

[8]  D. Shlomi,et al.  Duplicate Prescription Rates of Long-Acting Bronchodilator Inhalers. , 2022, Journal of aerosol medicine and pulmonary drug delivery.

[9]  A. Ruano-Raviña,et al.  Factors Related with Hospital Attendance and Mortality in Patients with COPD: A Case–Control Study in a Real-Life Setting , 2022, International journal of chronic obstructive pulmonary disease.

[10]  A. Liantonio,et al.  Chronic treatment of COPD: state of the art and real-world analysis of healthcare costs based on medication adherence data. , 2022, Recenti progressi in medicina.

[11]  D. Mannino,et al.  Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. , 2022, Respiratory medicine.

[12]  S. Bollmeier,et al.  Concordance between reported medication taking behavior and prescription instructions for patients with chronic obstructive pulmonary disease visiting community pharmacies. , 2022, Journal of the American Pharmacists Association : JAPhA.

[13]  B. Lumbreras,et al.  Patient’s awareness on COPD is the strongest predictor of persistence and adherence in treatment-naïve patients in real life: a prospective cohort study , 2021, BMC Pulmonary Medicine.

[14]  U. Sambamoorthi,et al.  Initial maintenance therapy adherence among older adults with asthma-COPD overlap. , 2021, The American journal of managed care.

[15]  R. Leidl,et al.  Can Adherence to and Persistence with Inhaled Long-acting Bronchodilators Improve the Quality of Life in Patients with Chronic Obstructive Pulmonary Disease? Results from a German Disease Management Program , 2021, Clinical Drug Investigation.

[16]  W. Midodzi,et al.  Measuring Medication Adherence in a Population-Based Asthma Administrative Pharmacy Database: A Systematic Review and Meta-Analysis , 2021, Clinical epidemiology.

[17]  R. Ray,et al.  Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study , 2021, BMC Pulmonary Medicine.

[18]  N. Chavannes,et al.  A Pharmacy-Based eHealth Intervention Promoting Correct Use of Medication in Patients With Asthma and COPD: Nonrandomized Pre-Post Study , 2021, Journal of medical Internet research.

[19]  L. Lix,et al.  Primary prescription adherence for obstructive lung disease in a primary care population , 2021, Allergy, Asthma & Clinical Immunology.

[20]  D. Milea,et al.  A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand , 2021, International Journal of COPD.

[21]  T. Omachi,et al.  Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.

[22]  A. Ismaila,et al.  Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice , 2021, International journal of chronic obstructive pulmonary disease.

[23]  D. Halpin,et al.  Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes , 2021, Pragmatic and observational research.

[24]  R. Young,et al.  Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database , 2021, International Journal of COPD.

[25]  I. Gilbert,et al.  Association of Nonmedical Switches in Inhaled Respiratory Medications with Disruptions in Care: A Retrospective Prescription Claims Database Analysis , 2021, Pulmonary Therapy.

[26]  G. Requena,et al.  The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study , 2021, International journal of chronic obstructive pulmonary disease.

[27]  B. Saini,et al.  COPD Management in Community Pharmacy Results in Improved Inhaler Use, Immunization Rate, COPD Action Plan Ownership, COPD Knowledge, and Reductions in Exacerbation Rates , 2021, International journal of chronic obstructive pulmonary disease.

[28]  B. Cosío,et al.  Assessing Adherence by Combining the Test of Adherence to Inhalers with Pharmacy Refill Records. , 2021, Journal of investigational allergology & clinical immunology.

[29]  R. Stanford,et al.  Development and validation of a drug adherence index for COPD , 2021, Journal of managed care & specialty pharmacy.

[30]  A. Nobili,et al.  Medication adherence in community-dwelling older people exposed to chronic polypharmacy , 2021, Journal of Epidemiology & Community Health.

[31]  D. Price,et al.  Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study , 2021, Respiratory Research.

[32]  V. Schabert,et al.  Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States , 2021, Therapeutic advances in respiratory disease.

[33]  J. Quint,et al.  Prescribing Pathways to Triple Therapy: A Retrospective Observational Study of Adults with Chronic Obstructive Pulmonary Disease in the UK , 2020, International journal of chronic obstructive pulmonary disease.

[34]  A. Costantini,et al.  Adherence and persistence analysis after three years in real-life of inhalation therapies used in the treatment of COPD , 2020, Current medical research and opinion.

[35]  J. Quint,et al.  Prescribing Pathways to Triple Therapy: A Multi-Country, Retrospective Observational Study of Adult Patients with Chronic Obstructive Pulmonary Disease , 2020, Pulmonary Therapy.

[36]  M. Miravitlles,et al.  Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain. , 2020, Archivos de bronconeumologia.

[37]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[38]  A. Cole,et al.  Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy , 2020, International journal of chronic obstructive pulmonary disease.

[39]  P. Kuna,et al.  Primary non-adherence to inhaled medications measured with e-prescription data from Poland , 2020, Clinical and Translational Allergy.

[40]  J. Fairburn-Beech,et al.  Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan , 2020, Current medical research and opinion.

[41]  Rongchang Chen,et al.  Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study , 2020, International journal of chronic obstructive pulmonary disease.

[42]  M. Beauchesne,et al.  Development of a Web-Based Tool Built From Pharmacy Claims Data to Assess Adherence to Respiratory Medications in Primary Care , 2020, Respiratory care.

[43]  F. Lapi,et al.  Adherence to COPD free triple inhaled therapy in the real-world: a primary care based study. , 2020, The clinical respiratory journal.

[44]  W. Leslie,et al.  Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study , 2020, Osteoporosis International.

[45]  Junqiao Chen,et al.  Methods for Measuring Multiple Medication Adherence: A Systematic Review. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[46]  Slawomir Nowaczyk,et al.  Pitfalls of medication adherence approximation through EHR and pharmacy records: Definitions, data and computation , 2020, Int. J. Medical Informatics.

[47]  R. Kayyali,et al.  A quantitative evaluation of adherence and inhalation technique among respiratory patients: An observational study using an electronic inhaler assessment device , 2020, International journal of clinical practice.

[48]  C. Gillespie,et al.  Medication adherence, health care utilization, and spending among privately-insured adults with chronic conditions in the United States, 2010-2016. , 2020, The American journal of medicine.

[49]  V. Welch,et al.  Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline , 2020, BMJ.

[50]  R. Stanford,et al.  Validation and Assessment of the COPD Treatment Ratio as a Predictor of Severe Exacerbations. , 2020, Chronic obstructive pulmonary diseases.

[51]  C. Chouaid,et al.  Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy , 2019, International journal of chronic obstructive pulmonary disease.

[52]  J. Fonseca,et al.  High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis , 2019, Clinical and Translational Allergy.

[53]  R. Stanford,et al.  Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol , 2019, International journal of chronic obstructive pulmonary disease.

[54]  P. Jacobs,et al.  Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada , 2019, International journal of chronic obstructive pulmonary disease.

[55]  P. Devillier,et al.  Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study , 2019, International journal of chronic obstructive pulmonary disease.

[56]  L. Smeeth,et al.  Cost saving of switching to equivalent inhalers and its effect on health outcomes , 2019, Thorax.

[57]  R. Stanford,et al.  Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study , 2019, International journal of chronic obstructive pulmonary disease.

[58]  C. Strange,et al.  A Retrospective Claims Analysis of Dual Bronchodilator Fixed-Dose Combination Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease. , 2019, Chronic obstructive pulmonary diseases.

[59]  T. Seaton,et al.  Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting. , 2019, Journal of the American Pharmacists Association : JAPhA.

[60]  K. Liao,et al.  The association between adherence and dementia in chronic obstructive pulmonary disease , 2019, Medicine.

[61]  E. Parker,et al.  Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA. , 2019, Respiratory medicine.

[62]  R. Stanford,et al.  Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population , 2019, International journal of chronic obstructive pulmonary disease.

[63]  M. Hiligsmann,et al.  Methods for Measuring Multiple Medication Adherence: A Systematic Review-Report of the ISPOR Medication Adherence and Persistence Special Interest Group. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[64]  A. Wallace,et al.  Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population. , 2019, Journal of managed care & specialty pharmacy.

[65]  A. Ismaila,et al.  COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners , 2018, International journal of chronic obstructive pulmonary disease.

[66]  W. Leslie,et al.  Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study , 2018, Archives of Osteoporosis.

[67]  S. Stemkowski,et al.  Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study , 2018, Journal of managed care & specialty pharmacy.

[68]  B. Lamprecht,et al.  Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD) , 2018, BMC Pulmonary Medicine.

[69]  Rongchang Chen,et al.  Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data , 2018, International journal of chronic obstructive pulmonary disease.

[70]  M. Miravitlles,et al.  Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care , 2018, npj Primary Care Respiratory Medicine.

[71]  C. Laursen,et al.  Nationwide use of theophylline among adults-A 20-year Danish drug utilisation study. , 2018, Respiratory medicine.

[72]  L. Parkin,et al.  Patterns of use of long‐acting bronchodilators in patients with COPD: A nationwide follow‐up study of new users in New Zealand , 2018, Respirology.

[73]  C. Groothuis-Oudshoorn,et al.  Association between poor therapy adherence to inhaled corticosteroids and tiotropium and morbidity and mortality in patients with COPD , 2018, International journal of chronic obstructive pulmonary disease.

[74]  K. Fox,et al.  Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy , 2018, Therapeutic advances in respiratory disease.

[75]  Juhee Park,et al.  Adherence to Inhaled Medications and its Effect on Healthcare Utilization and Costs Among High-Grade Chronic Obstructive Pulmonary Disease Patients , 2018, Clinical Drug Investigation.

[76]  A. Pottegård,et al.  Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study , 2018, Basic & clinical pharmacology & toxicology.

[77]  M. Bjarnadóttir,et al.  Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases , 2018, PharmacoEconomics.

[78]  P. Langenberg,et al.  The association of antidepressant treatment with COPD maintenance medication use and adherence in a comorbid Medicare population: A longitudinal cohort study , 2018, International journal of geriatric psychiatry.

[79]  Y. Kuo,et al.  Pattern and Adherence to Maintenance Medication Use in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease: 2008-2013. , 2018, Chronic obstructive pulmonary diseases.

[80]  G. Netzer,et al.  Adherence and healthcare utilization among older adults with COPD and depression. , 2017, Respiratory Medicine.

[81]  M. Beauchesne,et al.  Adherence and Persistence to Long-Acting Anticholinergics Treatment Episodes in Patients With Chronic Obstructive Pulmonary Disease , 2017, The Annals of pharmacotherapy.

[82]  G. Onder,et al.  Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacy , 2017, Geriatrics & gerontology international.

[83]  J. Gagne,et al.  Impact of hospitalization on medication adherence estimation in claims data , 2017, Journal of clinical pharmacy and therapeutics.

[84]  E. Menditto,et al.  Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications , 2017, Current medical research and opinion.

[85]  Dan Dediu,et al.  Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data , 2017, PloS one.

[86]  Lisa M. Law,et al.  Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study , 2017, Pragmatic and observational research.

[87]  A. Frølich,et al.  Ethnic Differences in Persistence with COPD Medications: a Register-Based Study , 2017, Journal of Racial and Ethnic Health Disparities.

[88]  M. Roset,et al.  Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study , 2017, International journal of chronic obstructive pulmonary disease.

[89]  K. Fox,et al.  Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population. , 2017, American health & drug benefits.

[90]  Richard B Reilly,et al.  The INCATM (Inhaler Compliance AssessmentTM): A comparison with established measures of adherence† , 2017, Psychology & health.

[91]  G. Cappai,et al.  Adherence to Long-Acting Bronchodilators After Discharge for COPD: How Much of the Geographic Variation is Attributable to the Hospital of Discharge and How Much to the Primary Care Providers? , 2017, COPD.

[92]  S. Annavarapu,et al.  Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients , 2016, International journal of chronic obstructive pulmonary disease.

[93]  Hossam M. Hammady,et al.  Rayyan—a web and mobile app for systematic reviews , 2016, Systematic Reviews.

[94]  V. Bollu,et al.  Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β2-Agonists , 2016, Drugs - Real World Outcomes.

[95]  C. Marra,et al.  Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial , 2016, Trials.

[96]  P. Lange,et al.  Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD. , 2016, Respiratory medicine.

[97]  K. Rascati,et al.  Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission , 2016, Journal of managed care & specialty pharmacy.

[98]  P. Langenberg,et al.  Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. , 2016, Annals of the American Thoracic Society.

[99]  B. Vrijens,et al.  UvA-DARE ( Digital Academic Repository ) What We Mean When We Talk About Adherence in Respiratory Medicine , 2016 .

[100]  B. Bender,et al.  Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy. , 2016, The journal of allergy and clinical immunology. In practice.

[101]  M. Ray,et al.  Association of Part D coverage gap with COPD medication adherence. , 2016, The American journal of managed care.

[102]  K. Koehorst-ter Huurne,et al.  Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related , 2016, International journal of chronic obstructive pulmonary disease.

[103]  M. Davoli,et al.  The impact of adherence to inhaled drugs on 5‐year survival in COPD patients: a time dependent approach , 2016, Pharmacoepidemiology and drug safety.

[104]  R. de Marco,et al.  Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease , 2016, COPD.

[105]  M. Bouvy,et al.  Proposal of Standardization to Assess Adherence With Medication Records , 2016, The Annals of pharmacotherapy.

[106]  J. Izquierdo,et al.  Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.

[107]  J. V. Boven,et al.  Effects of targeting disease and medication management interventions towards patients with COPD , 2016, Current medical research and opinion.

[108]  B. Celli,et al.  Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β 2-agonists , 2016, Journal of medical economics.

[109]  S. Landis,et al.  Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care , 2015, Respiratory Research.

[110]  S. Suissa,et al.  Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia. , 2015, Chest.

[111]  J. Darbà,et al.  The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients , 2015, International journal of chronic obstructive pulmonary disease.

[112]  K. Garey,et al.  Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[113]  Elizabeth Manias,et al.  Initial Medication Adherence-Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[114]  Dagny Ulrich,et al.  Inhaler Use in Hospitalized Patients with Chronic Obstructive Pulmonary Disease or Asthma: Assessment of Wasted Doses , 2015, Hospital pharmacy.

[115]  S. Jackson,et al.  Describing drivers of and barriers to persistence with tiotropium in patients with chronic obstructive pulmonary disease: a mixed‐methods approach , 2015, The International journal of pharmacy practice.

[116]  Shawn Donnelly,et al.  Clinical metric and medication persistency effects: evidence from a Medicaid care management program. , 2015, Population health management.

[117]  N. Maimon,et al.  Tiotropium as part of inhaled polytherapy: Adherence and associated health‐care utilization , 2015, Respirology.

[118]  Gimena Hernandez,et al.  Asthma inhaler adherence determinants in adults: systematic review of observational data , 2014, European Respiratory Journal.

[119]  S. Vegter,et al.  Impact of multiple-dose versus single-dose inhaler devices on COPD patients’ persistence with long-acting β2-agonists: a dispensing database analysis , 2014, npj Primary Care Respiratory Medicine.

[120]  D. Steinke,et al.  A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom , 2014, International journal of clinical practice.

[121]  K. Davis,et al.  Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study , 2014, International journal of chronic obstructive pulmonary disease.

[122]  M. Davoli,et al.  Use Patterns of Long-acting Bronchodilators in Routine COPD Care: The OUTPUL Study , 2014, COPD.

[123]  I. Naya,et al.  Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β2-agonists in obstructive lung diseases: a population-based, observational study , 2014, International journal of clinical practice.

[124]  J. Remon,et al.  Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. , 2014, British journal of clinical pharmacology.

[125]  J. Hallas,et al.  Primary non-adherence in general practice: a Danish register study , 2014, European Journal of Clinical Pharmacology.

[126]  M. Wensing,et al.  Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients , 2014, International Journal of Clinical Pharmacy.

[127]  A. Ismaila,et al.  Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients , 2014, Current medical research and opinion.

[128]  E. Mehuys,et al.  Accuracy of the Medication Adherence Report Scale (MARS-5) as a Quantitative Measure of Adherence to Inhalation Medication in Patients With COPD , 2014, The Annals of pharmacotherapy.

[129]  B. Stuart,et al.  Association between depression and maintenance medication adherence among Medicare beneficiaries with chronic obstructive pulmonary disease , 2014, International journal of geriatric psychiatry.

[130]  B. Stuart,et al.  Should Eligibility for Medication Therapy Management Be Based on Drug Adherence? , 2014, Journal of managed care pharmacy : JMCP.

[131]  M. Roebuck,et al.  Medication utilization and adherence in a health savings account-eligible plan. , 2013, The American journal of managed care.

[132]  K. Koehorst-ter Huurne,et al.  The influence of type of inhalation device on adherence of COPD patients to inhaled medication , 2013, Expert opinion on drug delivery.

[133]  J. van der Palen,et al.  Differences in Adherence to Common Inhaled Medications in COPD , 2013, COPD.

[134]  M. Beauchesne,et al.  Does Hospitalization Influence Patients’ Medication Adherence and Community Pharmacists’ Interventions? , 2013, The Annals of pharmacotherapy.

[135]  J. Steiner,et al.  Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases , 2013, Medical care.

[136]  B. Stuart,et al.  Increasing Medicare part D enrollment in medication therapy management could improve health and lower costs. , 2013, Health affairs.

[137]  K. Coyne,et al.  A systematic literature review of methodologies used to assess medication adherence in patients with diabetes , 2013, Current medical research and opinion.

[138]  Pamala A. Pawloski,et al.  Patient Characteristics Associated with Medication Adherence , 2013, Clinical Medicine & Research.

[139]  I. Licaj,et al.  Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease , 2013, Chronic respiratory disease.

[140]  Anand A. Dalal,et al.  Should Medicare rely on high drug spending as a criterion for medication therapy management programmes? , 2012 .

[141]  M. McHugh Interrater reliability: the kappa statistic , 2012, Biochemia medica.

[142]  D. Au,et al.  Predictors of Adherence to Inhaled Medications Among Veterans with COPD , 2012, Journal of general internal medicine.

[143]  T. Brennan,et al.  Impact of Medication Adherence on Absenteeism and Short-Term Disability for Five Chronic Diseases , 2012, Journal of occupational and environmental medicine.

[144]  Anand A. Dalal,et al.  Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. , 2012, The American journal of geriatric pharmacotherapy.

[145]  D. Au,et al.  Adherence to Long-Acting Inhaled Therapies among Patients with Chronic Obstructive Pulmonary Disease (COPD) , 2012, COPD.

[146]  Jeffrey K Aronson,et al.  A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.

[147]  J. Priest,et al.  Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy. , 2012, Population health management.

[148]  D. Au,et al.  The Influence of Informal Caregivers on Adherence in COPD Patients , 2012, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[149]  H. Shah,et al.  Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease , 2011, Patient preference and adherence.

[150]  J. Priest,et al.  Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. , 2011, Population health management.

[151]  R. Butler,et al.  Effects of nonadherence with prescription drugs among older adults. , 2011, The American journal of managed care.

[152]  A. Swensen,et al.  Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. , 2011, Respiratory medicine.

[153]  J. Fincham,et al.  Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs. , 2011, Population health management.

[154]  J. Lammers,et al.  Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. , 2011, Respiratory medicine.

[155]  E. Wu,et al.  Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers , 2011, Journal of medical economics.

[156]  Anand A. Dalal,et al.  Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease , 2010, International journal of chronic obstructive pulmonary disease.

[157]  L. Blais,et al.  Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication , 2010, Clinical therapeutics.

[158]  J. Remon,et al.  COPD Management in Primary Care: An Observational, Community Pharmacy–Based Study , 2010, The Annals of pharmacotherapy.

[159]  A. Pickard,et al.  Medication adherence and persistence in the last year of life in COPD patients. , 2009, Respiratory medicine.

[160]  Anand A. Dalal,et al.  Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies , 2009, Current medical research and opinion.

[161]  Bradley C Martin,et al.  An Empirical Basis for Standardizing Adherence Measures Derived From Administrative Claims Data Among Diabetic Patients , 2008, Medical care.

[162]  D. Haupt,et al.  Medication persistence among patients with asthma/COPD drugs , 2008, Pharmacy World & Science.

[163]  L. Ring,et al.  Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10‐year period , 2007, Journal of clinical pharmacy and therapeutics.

[164]  L. Ring,et al.  Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma/COPD medication , 2007, Pharmacoepidemiology and drug safety.

[165]  J. Lammers,et al.  Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. , 2007, Respiratory medicine.

[166]  D. Au,et al.  A Refill Adherence Algorithm for Multiple Short Intervals to Estimate Refill Compliance (ReComp) , 2007, Medical care.

[167]  D. Au,et al.  Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[168]  L. Ring,et al.  Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions , 2007, Pharmacoepidemiology and drug safety.

[169]  B. Bender,et al.  Adherence and persistence with fluticasone propionate/salmeterol combination therapy. , 2006, The Journal of allergy and clinical immunology.

[170]  K. Chan,et al.  Methods for evaluation of medication adherence and persistence using automated databases , 2006, Pharmacoepidemiology and drug safety.

[171]  Marsha A Raebel,et al.  Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.

[172]  S. Schneeweiss,et al.  Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. , 2006, Clinical therapeutics.

[173]  N. Anthonisen,et al.  Use of spirometry and respiratory drugs in Manitobans over 35 years of age with obstructive lung diseases. , 2005, Canadian respiratory journal.

[174]  J. Lammers,et al.  Persistence with inhaled corticosteroid therapy in daily practice. , 2004, Respiratory medicine.

[175]  D. Au,et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. , 2003, American journal of respiratory and critical care medicine.

[176]  R. Balkrishnan,et al.  A Comparison of Medication Adherence Indices to Assess Long-Term Inhaled Corticosteroid Medication Use , 2001, The Journal of asthma : official journal of the Association for the Care of Asthma.

[177]  R. Balkrishnan,et al.  Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. , 2000, Clinical therapeutics.

[178]  P. Bakke,et al.  How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? , 1999, American journal of respiratory and critical care medicine.

[179]  K. Matuszewski,et al.  Noncompliance with drug therapy for chronic obstructive pulmonary disease: a risk factor for hospitalization? , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[180]  S. Suissa,et al.  Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. , 1994, The European respiratory journal.

[181]  T D Koepsell,et al.  A General Method of Compliance Assessment Using Centralized Pharmacy Records: Description and Validation , 1988, Medical care.

[182]  R. Kaestner,et al.  Impact of Medication Adherence on Health Services Utilization in Medicaid , 2018, Medical care.

[183]  Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies , 2017 .

[184]  J. Virchow,et al.  Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset. , 2017, Respiratory medicine.

[185]  N. Chavannes,et al.  Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. , 2016, Respiratory medicine.

[186]  J. Hallas,et al.  Low Use and Adherence to Maintenance Medication in Chronic Obstructive Pulmonary Disease in the General Population , 2014, Journal of General Internal Medicine.

[187]  C. Bova,et al.  A Proposal for Quality Standards for Measuring Medication Adherence in Research , 2012, AIDS and Behavior.

[188]  S. Ramachandran,et al.  Original article Comparative effectiveness of budesonide/ formoterol and fluticasone/salmeterol for COPD management , 2011 .

[189]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[190]  Femida Gwadry-Sridhar,et al.  A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[191]  J. Cramer,et al.  Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[192]  J. Bourbeau,et al.  Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. , 2004, Canadian respiratory journal.

[193]  R. Shenolikar,et al.  COPD Medication Adherence and Persistence Among Managed Medicare Enrollees , 2022 .

[194]  M. Dransfield,et al.  Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Sequential Comparison of Tiotropium to High-dose Ipratropium in Patients with Chronic Obstructive Pulmonary Disease in a Practice Setting , 2022 .

[195]  T. Seemungal,et al.  International Journal of Copd Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Exacerbation Rate, Health Status and Mortality in Copd – a Review of Potential Interventions , 2022 .